Information courtesy of SeekWellness.com
http://www.seekwellness.com/controlling-overactive-bladder.htm
 
you are viewing incontinence > overactive bladder

  incontinence > overactive bladder



Protected by Copyscape Web Copyright Protection Software

control overactive bladder symptoms

by Diane K. Newman, DNP, FAAN, BCB-PMD

Overactive bladder symptoms can be controlled in a variety of ways.

Overactive bladder symptoms include:

advertisement
  • urinary urgency - sudden and strong sensation to urinate immediately
  • frequency – urinating often, usually more than 8 times in a day
  • nocturia – getting up more than twice at night to urinate
  • urinary incontinence – accidental leakage of urine

Many people find that specific diet, lifestyle changes and exercises may help reduce overactive bladder (OAB) symptoms and other bladder control problems.

Overactive bladder symptoms can often be controlled with pelvic muscle floor exercises

Bladder control depends on muscles working together when the bladder is filling: the bladder muscle should be relaxed and the muscles around the urethra (the tube that urine passes through) called the pelvic floor muscle should be tight. Exercises that strengthen the pelvic floor muscles can help hold urine inside the bladder, preventing leakage. These are commonly called “Kegel” or pelvic floor muscle exercises, named after the doctor who developed them.

To perform a pelvic floor muscle exercise, imagine that you are trying to control the passing of gas or pinching off a stool. Or imagine you are in an elevator full of people and you feel the urge to pass gas. What do you do? You tighten or pull in the ring of muscle around your rectum - your pelvic floor muscle. Women will feel a lifting sensation in the area around the vagina or pulling in of the rectum. Men may see their penis lift or a pulling in of the rectum. One exercise consist of both “tightening and relaxing” the muscle. Start by tightening the muscle for 5 seconds and build till you can hold the tightening or 10 seconds. Be sure to relax completely between each muscle tightening. (See Figures below).

Pelvic muscle - female pelvis   Pelvic muscle - male pelvis


Overactive bladder symptoms can often be controlled with bladder retraining 

Bladder control can be improved by scheduling bathroom trips. The schedule is changed over a period of weeks or months to gradually increase the time between trips. For example, a person who normally goes to the bathroom every hour could plan to go every hour and 15 minutes. After maintaining the new schedule for a few days, the time could be increased to every hour and 30 minutes. The goal is to void no more than every 3 to 4 hours. If you get the urge to void and it is not yet your scheduled voiding time; stop all activity and sit down if possible. Then try one of these techniques to help you lessen the urge, which will cause the bladder to relax, and give you more time to get to the bathroom:

  • Take some slow, deep breaths through your mouth, concentrating on your breathing; or concentrate on an activity, such as taking a vacation, visiting a friend, counting backwards from 100, or reciting the words of a favorite song or nursery rhyme.

  • Tighten your pelvic floor muscle quickly several times in a row.

Monitor your diet and medications to improve bladder control

Certain food and beverages can irritate the bladder and make overactive bladder symptoms worse. These include alcoholic beverages, caffeinated foods and/or carbonated beverages, (soft drinks, coffee or tea, chocolate), tomato-based products, citrus fruits and juices, spicy foods, and artificial sweeteners (e.g. Equal). Also some over-the-counter medications and prescription drugs can worsen bladder control problems such as Excedrin, Midol, Anacin, Dristan and Sinarest. Do not stop taking prescription drugs without talking to your healthcare provider first.

Maintain bowel regularity to lessen overactive bladder (OAB) symptoms

Keeping healthy bowel habits may lessen bladder control symptoms. Some suggestions include: 1) increase fiber-rich foods in your diet such as beans, pasta, oatmeal, bran cereal, whole wheat bread, fresh fruits and vegetables; 2) exercise to maintain regular bowel movements; 3) drink plenty of nonirritating fluids (water); 4) see your doctor if you have bowel problems.

Maintain a healthy weight to improve bladder control

Being overweight can put pressure on your bladder, which may cause leakage of urine when you laugh or cough. If you are overweight, weight loss can reduce pressure on your bladder.

advertisement

Stop smoking to lessen overactive bladder (OAB) symptoms

Cigarette smoking is irritating to the bladder muscle. It can also lead to coughing spasms which can cause urinary leakage and loss of bladder control.


References:

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.

Abrams P., Freeman, R, Anderstrom, C, Mattiasson, A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology. 1998;81:801-810.

Abrams P., Cardozo, L, Fall, M, Griffiths, D, Rosier, P, Ulmsten, U, et.al. The standardisation of terminology of lower urinary tract function. Neurourology and Urodynamics. 2002;21:167-178.

Anderson, K-E. New parmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004;ppl 3A):32-41.

Anderson, R., Mobley, D., Blank, B., Saltzman, D., Susset, J., Brown, J. Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. 1999; The Journal of Urology. 161:1809-1812.

Appell, R. Chancellor, M., Zobrist, H. Thomas, H.. Sanders, S.. Pharmacokinetics, metabolism and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clinical Proceedings. 2003;78:696-702.

Burnett, A., Davila, G Willy, Newman, Diane, Hardestry, S. Clinical and Cost-Effective Strategies in the Management of Urinary Incontinence. Managed Care Consultant. 2002;5-39.

Burgio K., Locher J., Goode P. Combined Behavioral and Drug Therapy for Urge Incontinence in Older Women. JAGS. 2000; 48: 370-374.

Chancellor M., Freedman, S, Mitcheson, HD, Antoci, J, Primus, G, Wein, A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigations. 2000;19:83-91.

Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60 (Suppl 5A):82-89.

Cruz, F. Mechanisms involved in new therapies for overactive bladder. Urology. 2004;sppl 3A):65-73.

Davila, G Willy, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. The Journal of Urology. 2001;166(1):140-145.

Diokno, A., Appell, R., Sand, P., Dmochowski, R., Gburek, B., Klimberg, I., Kell, S.. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clinical Proceedings. 2003;78:687-695.

Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urology. 2002;168:580-586.

Halaska, M., Ralph, G., Wiedeman, A., Rimus, G., Ballering, B., Hofner, K & Jona., G. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor overactivity. World J Urology. 2003;20:392-399.

Hampel, CC., Wienhold, D., Benken, N., Egersmann, C., Thuroff, JW. Definition of overactive bladder and epidemiology of urinary incontinence. Urology. 1997;50[suppl 6A]:4-14.

Hofner, K., Oelke, M., Machtens, S., Grunewald, V. Trospium chloride-an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urology. 2001;19:336-343.

Kelleher, Con. Economic and Social Impact of OAB. European Urology Supplements. 2002;1:11-16.

Kelleher, C, Pleil, A.M., Reese, P. R., Burgess S. M,, Brodish, P. H. How much is enough and who says so? The case of King's Health Questionnaire and overactive bladder. BJOG. 2004;111:605-612.

Hu TW, Wagner TH, Bentkover JD. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.

Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452-456.

Milsom, I, Stewart, W, Thuroff, JW The Prevalence of Overactive Bladder. The American Journal of Managed Care. 2000; 6(11), Sup:S565-S573.

Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol. 2000;1:361-368.

Newman, D.K. & Wein, A.J. Overcoming Overactive Bladder, New Harbinger, Los Angeles, California, 2004.

Newman, Diane. Managing and Treating Urinary Incontinence. Baltimore: Health Professions Press;2002.

Ouslander, J.O. Management of overactive bladder. JAMA 2004;350(8):786-799.

Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol. 2002;4(Suppl 4):S38-S43.

Stewart W, Herzog R, Wein A. The prevalence and impact of overactive bladder in the U.S.: results from the NOBLE program. 2001; Neurourology Urodynamics. 20:406-408.

Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(Suppl 5A):7-12.

Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. 2000; Int J Fertil Womens Med. 1999; 44: 56-66.

Zinner, N., Gittelman, M., Harris, R., Susset, J., Kanellos, A., Auerbach, S. Trospium cloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology. 2004;171:2311-2315.

Posted December 2003
Updated August 2009
  

advertisement

 
website design:
Web site design by Well Web Development
Online Payments
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.